Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki

被引:0
作者
Yaeko Hashimoto
Takuji Suzuki
Kenji Hashimoto
机构
[1] Chiba University Graduate School of Medicine,Department of Respirology
[2] Chiba University Center for Forensic Mental Health,Division of Clinical Neuroscience
来源
Molecular Psychiatry | 2022年 / 27卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:3563 / 3564
页数:1
相关论文
共 34 条
[1]  
Groff D(2021)Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review JAMA Netw Open 4 e2128568-3
[2]  
Sun A(2021)How COVID-19 affects the brain JAMA Psychiatry 78 682-3
[3]  
Ssentongo AE(2021)Positive Epstein-Barr virus detection in coronavirus disease 2019 (COVID-19) patients Sci Rep 11 763-58
[4]  
Ba DM(2021)Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation Pathogens 10 161-611
[5]  
Parsons N(2022)Old drug fluvoxamine, new hope for COVID-19 Eur Arch Psychiatry Clin Neurosci 272 249-undefined
[6]  
Poudel GR(2021)Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor Eur Arch Psychiatry Clin Neurosci 271 eaau5266-undefined
[7]  
Boldrini M(2019)Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis Sci Transl Med 11 1599-undefined
[8]  
Canoll PD(2014)In vivo intratumoral Epstein-Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications Mod Pathol 27 undefined-undefined
[9]  
Klein RS(undefined)undefined undefined undefined undefined-undefined
[10]  
Chen T(undefined)undefined undefined undefined undefined-undefined